PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Modified virus targets Hard-to-Treat melanoma in early trial
Disease control TerminatedThis early-phase trial tested a specially modified virus (VSV-IFNb-TYRP1) in 12 people with advanced melanoma that had spread or couldn't be removed. The virus was injected directly into tumors and into a vein to see if it could safely trigger the immune system to attack cancer c…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 26, 2026 04:38 UTC
-
Experimental cocktail aims to reboot immune attack on tough cancers
Disease control TerminatedThis early-phase study tested a drug called plinabulin combined with radiation and immunotherapy in 19 people with advanced cancers (like lung, bladder, or melanoma) that had stopped responding to standard immunotherapy. The goal was to see if the combination was safe and could s…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:30 UTC
-
Melanoma drug combo trial halted after just 3 patients
Disease control TerminatedThis study tested two drugs, encorafenib and binimetinib, given before surgery to people with a certain type of advanced melanoma (stage IIIB-D) that had spread to lymph nodes. The goal was to see if the drugs could shrink or eliminate the cancer before removal. The trial was sto…
Matched conditions: PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 20, 2026 11:53 UTC